The Australasian Resuscitation In Sepsis Evaluation: Fluids or vasopressors in emergency department sepsis (ARISE FLUIDS), a multi-centre observational study describing current practice in Australia and New Zealand by Keijzers, Gerben et al.
Bond University
Research Repository
The Australasian Resuscitation In Sepsis Evaluation: Fluids or vasopressors in emergency
department sepsis (ARISE FLUIDS), a multi-centre observational study describing current
practice in Australia and New Zealand
Keijzers, Gerben; Macdonald, Stephen P.J.; Udy, Andrew A.; Arendts, Glenn; Bailey, Michael;
Bellomo, Rinaldo; Blecher, Gabriel E.; Burcham, Jonathon; Coggins, Andrew R.; Delaney,
Anthony; Fatovich, Daniel M.; Fraser, John F.; Harley, Amanda; Jones, Peter; Kinnear,
Frances B.; May, Katya; Peake, Sandra; Taylor, David Mc D.; Williams, Patricia; ARISE
FLUIDS Observational Study Group
Published in:
EMA - Emergency Medicine Australasia
DOI:
10.1111/1742-6723.13469
Published: 01/08/2020
Document Version:
Publisher's PDF, also known as Version of record
Link to publication in Bond University research repository.
Recommended citation(APA):
Keijzers, G., Macdonald, S. P. J., Udy, A. A., Arendts, G., Bailey, M., Bellomo, R., Blecher, G. E., Burcham, J.,
Coggins, A. R., Delaney, A., Fatovich, D. M., Fraser, J. F., Harley, A., Jones, P., Kinnear, F. B., May, K., Peake,
S., Taylor, D. M. D., Williams, P., & ARISE FLUIDS Observational Study Group (2020). The Australasian
Resuscitation In Sepsis Evaluation: Fluids or vasopressors in emergency department sepsis (ARISE FLUIDS), a
multi-centre observational study describing current practice in Australia and New Zealand. EMA - Emergency
Medicine Australasia, 32(4), 586-598. https://doi.org/10.1111/1742-6723.13469
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository
coordinator.
Download date: 11 Sep 2020
ORIGINAL RESEARCH
The Australasian Resuscitation In Sepsis Evaluation:
Fluids or vasopressors in emergency department sepsis
(ARISE FLUIDS), a multi-centre observational study
describing current practice in Australia and
New Zealand
Gerben KEIJZERS ,1,2,3 Stephen PJ MACDONALD ,4,5 Andrew A UDY ,6,7 Glenn ARENDTS ,8
Michael BAILEY,6,9 Rinaldo BELLOMO,10,11 Gabriel E BLECHER ,12,13 Jonathon BURCHAM,4,5
Andrew R COGGINS ,14 Anthony DELANEY ,6,15,16,17 Daniel M FATOVICH ,4,5 John F FRASER,18,19,20
Amanda HARLEY,1,21,22 Peter JONES ,23,24 Frances B KINNEAR,18,25 Katya MAY,1 Sandra PEAKE,26,27,28
David McD TAYLOR 29,30 and Patricia WILLIAMS,26,27,28 on behalf of the ARISE FLUIDS Observational
Study Group
1Department of Emergency Medicine, Gold Coast University Hospital, Gold Coast, Queensland, Australia, 2School of Medicine, Bond University,
Gold Coast, Queensland, Australia, 3School of Medicine, Griffith University, Gold Coast, Queensland, Australia, 4Centre for Clinical Research in
Emergency Medicine, Harry Perkins Institute of Medical Research, Perth, Western Australia, Australia, 5Emergency Department, Royal Perth
Hospital, The University of Western Australia, Perth, Western Australia, Australia, 6Australian and New Zealand Intensive Care Research Centre,
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia, 7Department of Intensive Care and Hyperbaric
Medicine, The Alfred, Melbourne, Victoria, Australia, 8School of Medicine, The University of Western Australia, Perth, Western Australia, Australia,
9Department of Medicine and Radiology, The University of Melbourne, Melbourne, Victoria, Australia, 10Department of Intensive Care, Austin
Hospital, Melbourne, Victoria, Australia, 11School of Medicine, The University of Melbourne, Melbourne, Victoria, Australia, 12Emergency
Department, Monash Medical Centre, Monash Health, Melbourne, Victoria, Australia, 13Monash Emergency Research Collaborative, School of
Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia, 14Emergency Medicine and Trauma, Westmead Hospital,
Sydney, New South Wales, Australia, 15Malcolm Fisher Department of Intensive Care Medicine, Royal North Shore Hospital, Sydney, New
South Wales, Australia, 16Northern Clinical School, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia,
17Division of Critical Care and Trauma, The George Institute for Global Health, The University of New South Wales, Sydney, New South Wales,
Australia, 18Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia, 19Critical Care Research Group, The Prince
Charles Hospital, Brisbane, Queensland, Australia, 20Intensive Care Unit, St Andrew’s War Memorial Hospital, Brisbane, Queensland, Australia,
21Critical Care Management Team, Queensland Children’s Hospital, Brisbane, Queensland, Australia, 22The University of Queensland, Brisbane,
Queensland, Australia, 23School of Medicine, The University of Auckland, Auckland, New Zealand, 24Adult Emergency Department, Auckland
Correspondence: Professor Gerben Keijzers, Department of Emergency Medicine, Gold Coast University Hospital, 1 Hospital Bou-
levard, Southport, QLD 4215, Australia. Email: gerben.keijzers@health.qld.gov.au
Gerben Keijzers, MSc (Biomed Health Sci), MBBS, FACEM, PhD, Emergency Physician, Adjunct Professor; Stephen PJ Macdonald,
BSc, MBChB, PhD, FRCP, FACEM, Clinical Research Fellow, Emergency Physician; Andrew A Udy, BHB, MBChB, FCICM, PhD,
Intensive Care Physician; Glenn Arendts, MBBS, MMed, PhD, Emergency Physician, Professor; Michael Bailey, PhD, MSc
(Statistics), BSc (Hons), Head Statistician, Professor of Critical Care Trial Statistics; Rinaldo Bellomo, MBBS, MD, FCICM,
FRACP, Intensive Care Physician, Professor; Gabriel E Blecher, MBBS (Hons), PDM, FACEM, CCPU, MSc (Epi), Deputy Director
Emergency Department; Jonathon Burcham, BSc (Nursing), PGDip (Emergency Nursing), MACN, RN, Clinical Nurse Manager;
Andrew R Coggins, MBChB, FRCP (UK), FACEM, MAcadMEd, FRCEM, Staff Specialist; Anthony Delaney, MBBS, MSc, PhD,
FACEM, FCICM, Intensive Care Physician, Honorary Professorial Fellow; Daniel M Fatovich, MBBS, FACEM, PhD, Professor of
Emergency Medicine; John F Fraser, MBChB, PhD, FRCP, FRCA, FFARCSI, FCICM, Intensive Care Physician, Professor; Amanda
Harley, BN, GradDipEd, MEmergN, Paediatric Sepsis Clinical Nurse Consultant; Peter Jones, MBChB, MSc (Oxon), PhD,
FACEM, Emergency Physician, Associate Professor; Frances B Kinnear, BSc (Hons), MBChB, PhD, FACEM, Senior Lecturer, Direc-
tor of Research, Senior Emergency Medicine Specialist; Katya May, BA, MSN, PhD, Nurse Researcher; Sandra Peake, BMBS, BSc
(Hons), FCICM, PhD, Director Intensive Care Medicine, Professor; David McD Taylor, MBBS, DRCOG, MPH, MD, FACEM,
FIFEM, Academic Emergency Physician, Professor; Patricia Williams, BNP (Intensive Care), Research Coordinator.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited.
Accepted 7 January 2020
© 2020 The Authors. Emergency Medicine Australasia published by John Wiley & Sons Australia, Ltd on behalf of Australasian College
for Emergency Medicine
Emergency Medicine Australasia (2020) doi: 10.1111/1742-6723.13469
City Hospital, Auckland, New Zealand, 25Emergency and Children’s Services, The Prince Charles Hospital, Brisbane, Queensland, Australia,
26Department of Intensive Care Medicine, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia, 27Faculty of Health and Medical
Sciences, School of Medicine, Adelaide University, Adelaide, South Australia, Australia, 28School of Epidemiology and Preventive Medicine,
Monash University, Melbourne, Victoria, Australia, 29Emergency Medicine Research, Austin Hospital, Melbourne, Victoria, Australia, and
30Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia
Abstract
Objectives: To describe haemodynamic
resuscitation practices in ED patients
with suspected sepsis and hypotension.
Methods: This was a prospective,
multicentre, observational study con-
ducted in 70 hospitals in Australia and
New Zealand between September
2018 and January 2019. Consecutive
adults presenting to the ED during a
30-day period at each site, with
suspected sepsis and hypotension (sys-
tolic blood pressure <100 mmHg)
despite at least 1000 mL fluid resusci-
tation, were eligible. Data included
baseline demographics, clinical and
laboratory variables and intravenous
fluid volume administered, vasopressor
administration at baseline and 6- and
24-h post-enrolment, time to antimi-
crobial administration, intensive care
admission, organ support and in-
hospital mortality.
Results: A total of 4477 patients were
screened and 591 were included with a
mean (standard deviation) age of
62 (19) years, Acute Physiology and
Chronic Health Evaluation II score
15.2 (6.6) and a median (interquartile
range) systolic blood pressure of
94 mmHg (87–100). Median time to
first intravenous antimicrobials was
77 min (42–148). A vasopressor infu-
sion was commenced within 24 h in
177 (30.2%) patients, with noradrena-
line the most frequently used (n = 138,
78%). A median of 2000 mL
(1500–3000) of intravenous fluids was
administered prior to commencing
vasopressors. The total volume of fluid
administered from pre-enrolment to
24 h was 4200 mL (3000–5661), with
a range from 1000 to 12 200 mL. Two
hundred and eighteen patients (37.1%)
were admitted to an intensive care unit.
Overall in-hospital mortality was 6.2%
(95% confidence interval 4.4–8.5%).
Conclusion: Current resuscitation
practice in patients with sepsis and
hypotension varies widely and occupies
the spectrum between a restricted vol-
ume/earlier vasopressor and liberal
fluid/later vasopressor strategy.
Key words: emergency department,
fluid therapy, hypotension, sepsis,
vasopressor.
Introduction
Hypotension in sepsis results from a
variable combination of fluid extravasa-
tion, peripheral vasodilatation and
myocardial depression.1 A cornerstone
of immediate management is the
administration of intravenous (IV) fluid,
followed by commencement of a vaso-
pressor infusion if hypotension and/or
poor end-organ perfusion persists. In
the absence of high-quality evidence to
support specific fluid volumes, a
30 mL/kg or greater IV fluid bolus is
recommended by the Surviving Sepsis
Campaign.2 However, the evaluation of
a protocolised sepsis care bundle in
almost 50 000 patients did not find any
association between administration of
30 mL/kg IV fluid within 3 h of ED
presentation, and differential mortality.3
Despite the almost universal clinical
acceptance of fluid administration in
sepsis, there are multiple studies that
suggest possible harm from the liberal
use of this intervention.4–10 As these
studies were conducted in intensive
care settings,4,5 conducted in low-
income countries,6–8 or involved pre-
clinical models,10 their findings cannot
be generalised to adults presenting to
the ED with suspected sepsis in
Australia and New Zealand. Indeed,
an alternative approach to sepsis resus-
citation is earlier initiation of vasopres-
sor infusions, with observational
studies reporting increased mortality
when this is delayed.11,12 Moreover, a
recent single centre double-blind
randomised controlled trial conducted
in a tertiary hospital in Thailand dem-
onstrated that administration of low-
dose noradrenaline resulted in greater
shock resolution by 6 h, as compared
with placebo (75 vs 48%).13
Accordingly, the optimal volume
and timing of fluid resuscitation
and initiation of vasopressor sup-
port in patients with sepsis and
hypotension represent significant
knowledge gaps.14–16 A comprehensive
understanding of current resuscitation
practices is essential for the design and
conduct of future large-scale clinical
trials evaluating the effects of alterna-
tive strategies (such as restricted fluid
therapy combined with early vasopres-
sor use), in patients presenting to the
ED with septic shock.
As such, the aim of the Australasian
resuscitation in sepsis evaluation:
Fluid or vasopressors in ED sepsis
(ARISE FLUIDS) observational study
was to describe current resuscitation
practices and outcomes in patients
presenting to the ED with sepsis, spe-
cifically to determine: (i) current IV
fluid and vasopressor administration;
(ii) in-hospital mortality and receipt
of organ support; and (iii) the inci-
dence of patients presenting to the ED
with sepsis and hypotension.
Methods
Design, setting and participants
The methodology of the ARISE
FLUIDS observational study has
been published previously,17 and
was endorsed by the Australasian
Key findings
• The optimal volume and
timing of fluid resuscitation
and initiation of vasopressor
support in patients with sepsis
and hypotension is unknown.
• Current resuscitation practices
in patients with sepsis and
hypotension vary widely in
our study, with fluid volume
given in the first 24 hours
ranging from 1–12 L.
• This study will inform the
design of a randomised con-
trolled trial comparing a
restricted volume (earlier
vasopressor) to a liberal fluid
(later vasopressor) strategy.
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College for Emergency Medicine
Clinical Trials Network. Human
Research and Ethics and governance
approval was obtained for all sites
according to local requirement and
data collection with a waiver of
patient consent was approved.
Briefly, ARISE FLUIDS was a pro-
spective, multi-centre observational
study conducted in 70 EDs in
Australia and New Zealand, where
individual sites could select a consecu-
tive 30-day data collection period
commencing between 13 September
2018 and 15 December 2018, with
final data collected on 13 January
2019. During the site-selected data col-
lection period, adult patients presenting
to the ED were eligible for inclusion if
they met the following inclusion
criteria: (i) clinically suspected infec-
tion; (ii) IV antimicrobials commenced;
and (iii) systolic blood pressure (SBP)
<100 mmHg at any time in ED despite
at least 1000 mL IV fluid resuscitation.
This had to be given as fluid
bolus(es) of at least 500 mL, within
60 min per bolus, inclusive of pre-
hospital fluids. Exclusion criteria
were: (i) hypotension suspected to be
due to another cause e.g. arrhyth-
mia, haemorrhage; (ii) confirmed or
suspected pregnancy; (iii) comorbidities
such that intensive care unit (ICU) or
high dependency unit admission for
vasopressor use is not appropriate;
(iv) death deemed imminent or inevita-
ble by the treating clinician; (v) life
expectancy <90 days due to an under-
lying illness; and (vi) transfer from
another acute care hospital.
Screening, data collection and
follow-up
All sites were provided with a
preformatted screening form and
standardised education material to
optimise screening, identification of
eligible patients and data collection.
For patients meeting all study entry
criteria (Fig. 1), a detailed case report
form was completed.17 Relevant vari-
ables and outcomes included: (i)
baseline demographics and com-
orbidities; (ii) vital signs and labora-
tory variables at baseline and at 6 h
post-enrolment; (iii) type, timing and
dose of IV fluid and vasopressor
administration from ED presentation
up to 24 h post-enrolment (including
fluids administered pre-hospital);
(iv) time to commencing the first IV
antimicrobial agent; (v) source of sep-
sis and source control; (vi) ED dura-
tion of stay; (vii) ICU/high dependency
unit admission; and (viii) in-hospital
mortality. For patients admitted to the
ICU, we collected additional informa-
tion on ICU duration of stay and
receipt and duration of invasive
mechanical ventilation, vasopressors
and acute renal replacement therapy.
De-identified data were entered by
local site investigators or the coordi-
nating site into a purpose-built web-
based database (REDCap®) hosted
by the Australian and New Zealand
Intensive Care Research Centre,
Monash University. The ARISE
FLUIDS study conforms to the
STROBE principles for reporting of
observational studies.18
Statistical analysis
We did not perform a formal sample
size calculation as this was a descriptive
study. The analysis plan anticipated
data collection on 400 patients.17 Con-
tinuous variables are reported as mean
and standard deviation (SD) or median
and interquartile range (IQR) and cate-
gorical variables as proportions (%) as
appropriate. Baseline characteristics,
process-of-care measures (e.g. fluid vol-
ume at 6- and 24-h post-enrolment and
frequency, timing and duration of vaso-
pressor administration) and outcomes
(e.g. ED disposition, ICU admission,
receipt and duration of organ support
and in-hospital mortality) are reported.
Subgroups based on pre-enrolment
characteristics were specified a priori:
(i) hospital type (rural/regional, metro-
politan/district, private, tertiary);
(ii) age <65 versus ≥65 years;
(iii) quartiles of the Acute Physiology
and Chronic Health Evaluation
(APACHE II) score at T0; (iv) presence
of cardiovascular disease; (v) SBP <90
versus ≥90 mmHg; (vi) lactate <2.0
versus ≥2.0 mmol/L; (vii) SBP
<90 mmHg and lactate ≥2.0 mmol/L
and first dose of IV antimicrobials
commenced patients versus patients
not meeting these criteria; (vi) source
of sepsis; abdominal source versus
other; respiratory source versus other;
(vii) quartiles of fluid volume adminis-
tered up to 6 h post-enrolment; and
(viii) quartiles of time to commencing
a vasopressor infusion. Between-
group differences in in-hospital mor-
tality, ICU admission and receipt and
duration of organ support were com-
pared for the quartiles of volume of
fluid administered and quartiles of
time to commencing vasopressors
sub-groups. Chi-squared or Fisher’s
exact test for categorical variables
were used and Student’s t-test or
Mann–Whitney U-test used for con-
tinuous variables.
Results
The 70 participating EDs had a com-
bined adult patient attendance during
their respective 30-day data collec-
tion periods of 295 904 patients. Of
4477 patients screened, 591 (13.2%)
patients met the eligibility criteria for
detailed data collection (Fig. 1).
4477 screened for eligibility, 
reported by sites
177 patients excluded†
- Age <18 years (n = 4)
- Hypotension due to non-sepsis cause (n = 42)
- Pregnant (n = 5)
- Fluids or vasopressors not appropriate (n = 78)
- Life expectancy <90 days (n = 33)
- Transfer from another hospital (n = 35)
- Death deemed imminent or inevitable (n = 26)
591 eligible 
768 met all three inclusion criteria
Figure 1. Patient flowchart. †Some patients met >1 exclusion criterion.
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Baseline characteristics
Baseline characteristics are summarised in
Table 1. The mean (SD) age was 62.4
(19.1) years and APACHE II score 15.2
(6.7). The median time from ED presen-
tation to commencing IV antimicrobials
was 77 (IQR 42–148) minutes. More
than one-third (37.6%, n = 222) had no
prior co-morbidities and 9.8% (n = 58)
lived in a residential care setting. Table S1
portrays vital signs, blood gas analyses,
receipt of invasive ventilation and labora-
tory data at baseline, 6, and 24 h.
Fluid resuscitation and
vasopressor therapy
Table 2 and Figure 2 summarise fluid
and vasopressor administration up to
24 h post-enrolment (including pre-
hospital fluids) for the overall cohort
and the SBP and lactate subgroups.
Overall, the fluid volume administered
in the first 6 h post-enrolment was
1789 mL (1000–2500) and, from pre-
enrolment to 24 h post-enrolment,
4200 mL (3000–5661). Patients with
a baseline SBP <90 mmHg, lactate
≥2 mmol/L or both, received total
median fluid volumes of 4582, 4645
and 4805 mL up to 24 h, respectively.
The majority of resuscitation fluid in
the first 24 h consisted of 0.9% saline
and balanced isotonic fluid (Table S2).
Almost one-third of patients (30.2%,
n = 177) received a vasopressor infu-
sion in the first 24 h post-enrolment,
with noradrenaline (78%, n = 138)
and metaraminol (42%, n = 74) most
frequently used (Table 3). In patients
with a SBP <90 mmHg at baseline,
48.4% (n = 92) received a vasopressor
infusion up to 24 h post-enrolment
and in patients with a SBP <90 mmHg
and a lactate ≥2 mmoL/L, almost two-
thirds (64.6%, n = 53) received a vaso-
pressor. A central venous catheter or
peripherally inserted central catheter
were inserted in the first 24 h in
126 patients (21.5%).
Clinical outcomes
Overall, one-third (33.7%, n = 198) of
patients had a respiratory source and a
quarter (25.0%, n = 147) had a uri-
nary source, with no source found in
10.2% (n = 60). The median ED
length of stay was 7.9 h (5.4–13.4)
and over one-third (37.1%, n = 218)
of patients were admitted to an inten-
sive care setting in the first 24 h. ICU
admission rates were higher for the
TABLE 1. Baseline characteristics and comorbidities at T0 (n = 591)
Variable n
Age, years, mean (SD) 62.4 (19.1) 583
Female sex, n (%) 290 (49.2) 590
Weight, kg, median (IQR) 75 (62.3–90) 363
Lactate, mmol/L, median (IQR) 2.2 (1.4–3.4) 474
APACHE II score, mean (SD) 15.2 (6.67) 590
Time from triage to T0, h, median
(IQR)
2.43 (1.28–4.28) 590
Time from triage to first IV
antimicrobials, min, median (IQR)
77 (42–148) 584
Total fluid volume prior to T0, mL,
median (IQR)
1000 (1000–1500) 590
Invasive ventilation, n (%) 4 (0.86) 466
Non-invasive ventilation, n (%) 17 (3.6) 567
Prior living status, n (%) 589
Home 526 (89.3)
Residential care 58 (9.8)
Comorbidities, n (%) 591
Respiratory disease 150 (25.4)
Immuno-suppressed 151 (25.6)
Cardiac disease 190 (32.1)
Liver disease 40 (6.8)
Renal dialysis 27 (4.6)
None 222 (37.6)
T0 is defined as the time when all three inclusion criteria were met. Com-
orbidities as defined as per APACHE II definitions. Invasive ventilation indi-
cates mechanical ventilation. APACHE II, Acute Physiology and Chronic
Health Evaluation.
Figure 2. Intravenous fluid volumes
administered in all eligible patients (n = 591).
Box plots with median and IQR shown.
Yellow:mean and standard deviation.
© 2020 The Authors. Emergency Medicine Australasia published by John Wiley & Sons Australia, Ltd on behalf of Australasian College
for Emergency Medicine
4 G KEIJZERS ET AL.
TABLE 2. Fluid volume and vasopressor use, for overall group and selected subgroups
Overall
(n = 591)
SBP <90
(n = 191)
Lactate ≥2
(n = 264)
SBP <90 and
lactate ≥2 (n = 82)
Total fluid administered, mL
Pre-T0 h
Median (IQR) 1000 (1000–1500) 1000 (1000–1500) 1000 (1000–1900) 1000 (1000–1900)
Mean (SD) 1389 (647) 1377 (642) 1461 (669) 1486 (753)
Between T0 and T6 h
Median (IQR) 1789 (1000–2500) 2000 (1250–3000) 2000 (1000–3000) 2015 (1320–300)
Mean (SD) 1908 (1230) 2254 (1252) 2126 (1244) 2317 (1231)
Between T6 and T24 h
Median (IQR) 1000 (200–2000) 1200 (500–2000) 1165 (540–2000) 1250 (625–2000)
Mean (SD) 1273 (1111) 1383 (1085) 1394 (1111) 1354 (1031)
Total: preT0-T24 h
Median (IQR) 4200 (3000–5661) 4582 (3500–6200) 4645 (3498–6108) 4805 (3900–6170)
Mean (SD) 4518 (1980) 4962 (1986) 4936 (1973) 5124 (1883)
Vasopressors started in ED, n (%) 134 (22.7) 74 (38.7) 84 (31.8) 42 (51.2)
Total fluid volume prior starting vasopressor infusion, mL
Median (IQR) 2000 (1500–3000) 2000 (1500–3000) 2000 (1500–3000) 2000 (1250–3000)
Mean (SD) 2465 (1280) 2255 (1258) 2461 (1292) 2297 (1394)
Vasopressor infusion started
before T24, n (%)
177 (30.2) 92 (48.4) 114 (43.3) 53 (64.6)
Time from Triage to start of vasopressor
infusion, h, median (IQR)
4.7 (2.7–7.8) 4.2 (2.2–7.0) 3.8 (2.3–6.7) 3.5 (2.1–6.3)
Time from T0 to start of vasopressor
infusion, h, median (IQR)
2.5 (0.8–5.0) 2.0 (0.6–4.5) 1.9 (0.7–4.5) 1.8 (0.4–3.1)
Duration of vasopressor
infusion, h, median (IQR)
26.2 (12–48) 31 (15.6–52) 29.8 (15–59) 32.1 (19–69)
Type and median duration of individual vasopressors
Noradrenaline, n (%) 138 (78) 70 (76.1) 95 (83.3) 43 (81.1)
Duration, h, median (IQR) 5.27 (3.0–9.2) 31 (17–50) 33 (14–54) 39 (19.5–55)
Metaraminol, n (%) 74 (42) 38 (41.8) 45 (39.5) 20 (37.7)
Duration, h, median (IQR) 5.8 (2.7–26) 7 (2.4–26) 4 (2.4–17.1) 4 (2.4–17.2)
Adrenaline, n (%) 15 (8.6) 11 (12.2) 11 (9.8) 7 (13.5)
Duration, h, median (IQR) 4.6 (2.0–13.8) 11 (5.5–22.7) 13.7 (3.3–32) 19.6 (5.5–42)
Vasopressin, n (%) 19 (10.9) 10 (11.1) 18 (16.1) 7 (13.5)
Duration, h, median (IQR) 10.8 (5.4–15.1) 22.7 (17–29) 21.2 (16–36) 19.7 (16–23)
Dobutamine, n (%) 4 (2.3) 2 (2.2) 3 (2.7) 1 (1.9)
Duration, h, median (IQR) 9.1 (3.6–33.5) N/A N/A N/A
CVC or PICC inserted before T24 hrs 126 (21.5) 65 (34.2) 94 (35.7) 41 (50.0)
Time from Triage to CVC/PICC
insertion, hrs, median (IQR)
6.5 (3.5–10.1) 5.9 (3.5–8.9) 6.1 (3.0–8.9) 6.2 (3.5–8.0)
Fluid volumes did not include maintenance fluids. T0 is defined as the time when all three inclusion criteria were met.
CVC, central venous catheter; PICC, peripherally inserted central catheter.
© 2020 The Authors. Emergency Medicine Australasia published by John Wiley & Sons Australia, Ltd on behalf of Australasian College
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TABLE 3. Outcomes. Source of sepsis, ED disposition, ICU outcomes and organ support and mortality, for overall group
and selected subgroups
Overall
(n = 581)
SBP <90
(n = 191)
Lactate ≥2
(n = 264)
SBP <90 and
lactate ≥2 (n = 82)
Source of sepsis, n (%)
Respiratory 198 (33.7) 64 (33.5) 88 (33.3) 25 (30.5)
Urinary 147 (25.0) 45 (23.6) 58 (22) 20 (24.4)
Skin/soft tissue 67 (11.4) 28 (14.7) 29 (11) 11 (13.4)
Bloodstream 14 (2.4) 4 (2.1) 7 (2.7) 3 (3.7)
Abdo/pelvis 80 (13.6) 24 (12.6) 43 (16.3) 10 (12.2)
Central nervous system 6 (1) 0 (0) 2 (0.8) 0 (0)
Bone/joint 7 (1.2) 3 (1.6) 4 (1.5) 1 (1.2)
Other 9 (1.5) 2 (1) 2 (0.8) 1 (1.2)
No source found 60 (10.2) 20 (10.5) 29 (11) 10 (12.2)
Source control procedures performed, n (%) 50 (8.5) 21 (11.1) 9.1 (24) 10 (12.2)
Discharge destination from ED, n (%)
ICU 172 (29.4) 84 (44.4) 109 (41.6) 46 (57.5)
HDU 30 (5.1) 13 (6.9) 14 (5.3) 5 (6.3)
CCU 14 (2.4) 0 (0) 2 (0.8) 0 (0)
Ward 314 (53.7) 74 (39.2) 115 (43.9) 21 (26.3)
ED short stay ward 11 (1.9) 3 (1.6) 1 (0.4) 0 (0)
Operating theatre 13 (2.2) 6 (3.2) 8 (3.1) 2 (2.5)
Transfer to other hospital 31 (5.3) 9 (4.8) 11 (4.2) 4 (5.0)
ED length of stay, h, median (IQR) 7.9 (5.35–13.4) 7.3 (4.8–11) 7.7 (5.1–11.5) 6.5 (4.3–9.8)
ICU outcomes
Admitted to ICU within 24 h, n (%) 218 (37.1) 107 (56.6) 132 (50.0) 54 (65.9)
ICU duration of stay,
days, median (IQR)
2.4 (1.3–4.6) 2.4 (1.2–4.5) 2.7 (1.5–4.6) 2.7 (1.7–4.5)
Patients receiving invasive
ventilation, n (%)
36 (16.7) 14 (13.3) 27 (20.8) 8 (15.1)
Duration of ventilation,
days, median (IQR)
5.6 (2.0–7.08) 4.35 (1.8–7.5) 5.5 (1.9–7.3) 4.4 (1.9–7.7)
Patients receiving acute (RRT), n (%) 13 (6.1) 7 (6.7) 8 (6.3) 3 (5.8)
Duration of RRT, days, median (IQR) 2.2 (0.6–8.1) 4.0 (0.2–6.8) 3.1 (0.7–8.8) 4.0 (0.2–6.8)
Hospital outcomes
Hospital length of stay, days, median (IQR) 5.1 (2.8–10.1) 6.2 (3.6–12) 7.1 (4.0–15) 8.4 (4.0–15)
Discharge destination for survivors, n (%)
Home 451 (79.8) 137 (75.7) 202 (80.2) 62 (80.5)
Care facility 79 (14) 27 (14.9) 29 (11.5) 9 (11.7)
Mortality, n (%)
ED 4 (0.7) 2 (1) 2 (0.8) 2 (2.4)
ICU 18 (8.6) 8 (7.8) 12 (9.4) 1 (2)
In-hospital 36 (6.2) 17 (9.3) 21 (8.2) 6 (7.8)
ICU outcomes uses number of patients admitted to ICU as denominator. HDU, high dependency unit; RRT, renal replace-
ment therapy.
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TABLE 4. Baseline characteristics, fluid volume, need for organ support and mortality; overall group and by quartiles of
fluid administered T0–T6
Overall
(n = 584)
0–1000 mL
(n = 188)†
1001–1800 mL
(n = 104)
1801–2501 mL
(n = 147)
>2501 mL
(n = 145)
Female, n (%) 286 (49) 87 (46.3) 49 (47.1) 78 (53.1) 72 (49.7)
Age, years 62.5 (19.1) 65.8 (19) 61.3 (16.6) 61.6 (18.6) 59.8 (19.2)
Lactate, mmol/L 2.2 (1.4–3.4) 1.8 (1.3–3.1) 2.1 (1.3–3.4) 2.2 (1.5–3.4) 2.8 (1.8–4.1)
APACHE II score 15.2 (6.7) 14.4 (6.4) 14.5 (6.3) 15.2 (6.5) 16.6 (7.3)
SBP, mmHg 94.8 (13.7) 97.4 (12.5) 94.3 (11) 94.5 (14) 91.8 (16.1)
Time from triage to
antibiotics, mins
77 (42–147) 85 (46–172) 97 (41–180) 77 (47–135) 59 (34–117)
Fluid volume
administered, mL
Pre-T0 h
Median (IQR) 1000 (1000–1500)1000 (1000–1535)1000 (1000–1500)1000 (1000–1500)1000 (1000–2000)
Mean (SD) 1389 (647) 1362 (571) 1410 (743) 1330 (564) 1442 (678)
Between T0 and T6 h
Median (IQR) 1789 (1000–2500) 900 (469–1000) 1400 (1250–1538)2000 (2000–2306)3200 (3000–4000)
Mean (SD) 1908 (1230) 689 (380) 1404 (212) 2141 (211) 3612 (871)
Between T6 and T24 h
Median (IQR) 1000 (200–2000) 1000 (0–1825) 1250 (759–1883) 1000 (0–2000) 1550 (850–2370)
Mean (SD) 1273 (1111) 975 (1091) 1369 (993) 1275 (1121) 1590 (1119)
Total: pre-T0 and T24 h
Median (IQR) 4200 (3000–5661)3000 (2000–4000)4000 (3300–4792)4500 (3753–5675)5350 (3600–6250)
Mean (SD) 4543 (1969) 3011 (1348) 4183 (1269) 4729 (1316) 6600 (1724)
Total fluid volume
administered
prior to starting
vasopressors, mL, n
134 23 22 37 50
Median (IQR) 2000 (1500–3000)1750 (1125–3000)2000 (1500–2500)2000 (1850–3800)2750 (2000–3500)
Mean (SD) 246 (1280) 1887 (981) 2072 (935) 2492 (1220) 2894 (1440)
Vasopressor infusion
started in ED, n (%)
132 (22.6) 23 (12.2) 22 (21.1) 37 (25.2) 50 (34.5)
Vasopressor infusion
started before T24, n (%)
176 (30.1) 36 (19.1) 27 (26) 44 (29.9) 69 (47.6)
Duration of vasopressor
infusion, h, median (IQR)
26.6 (12–48) 24.5 (11–38) 21.7 (6–45) 17.5 (8–48) 36 (22–69)
Time to start
vasopressor infusion
from T0, h,
median (IQR)
2.5 (0.9–5.0) 2.4 (1.2–4.7) 2.1 (0.5–5.4) 2.1 (0.7–5.5) 2.7 (1.0–5.3)
ICU outcomes
Admitted to ICU
within 24 h, n (%)
217 (37.2) 45 (23.9) 32 (30.8) 53 (36.1) 87 (60.0)
Patients receiving
invasive ventilation, n (%)
36 (16.7) 4 (9.1) 4 (12.5) 9 (17.0) 19 (22.1)
(Continues)
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subgroups SBP <90 mmHg (56.6%,
n = 107) and SBP <90 mmHg and lac-
tate ≥2 mmol/L (65.9%, n = 54). For
patients admitted to ICU within 24 h,
the median length of stay was 2.4 days
(1.3–4.6). One in six (16.7%, n = 36)
patients admitted to ICU received
invasive ventilation and 6.1% (n = 13)
received acute renal replacement ther-
apy. Hospital duration of stay for the
whole patient cohort was 5.1
(2.8–10.1) days with an in-hospital
mortality of 6.2% (95% confidence
interval 4.5–8.5%).
Subgroup analyses by fluid
volume and time to vasopressor
infusion
Pre-specified sub-group analyses are
provided in Tables S3–S11. Tables 4,5
show the clinical outcomes according
to the volume of fluid administered in
the 6 h post-enrolment and the timing
of commencing a vasopressor infusion.
The highest fluid quartile received
more than 5 times the fluid volume
as the lowest quartile in the first 6 h
post-enrolment (3612 vs 689 mL)
and twice as much in the first 24 h
(6600 vs 3011 mL). Between quartile
1 and quartile 4, there was an
increase in vasopressor initiation
(from 19.1 to 47.6%), ICU admis-
sion (from 23.9 to 60%) and receipt
of invasive ventilation (from 9.1 to
22.1%) (Table 4). Duration of
vasopressor therapy varied between
17.5 and 24.5 h in the lowest three
fluid quartiles and was 36 (IQR
22–69) hours in the highest fluid
quartile. Although in-hospital mor-
tality was similar across all fluid
quartiles, duration of hospital stay
was 4.5 days in quartile 1 and
7.0 days in quartile 4.
The quartile of patients who com-
menced a vasopressor infusion the
earliest (within 2.7 h of ED presenta-
tion) tended to be older and tended
to have a higher baseline lactate and
APACHE II score as well as a lower
SBP compared to the remaining quar-
tiles (Table 5). The total volume of
fluid administered between 0 and 6 h
and up to 24 h was similar across the
vasopressor quartiles, although the
quartile of patients who received vaso-
pressors the latest (after 7.71 h), were
given most fluid (3500 mL [3000–
4100]) prior to commencement of vaso-
pressors. The in-hospital mortality for
patients receiving vasopressors was
13.1% (n = 23) with a median hospital
length of stay of 8.6 (4.4–18) days.
Discussion
Key findings
Our study provides critical contempo-
rary data concerning sepsis resuscitation
in EDs throughout Australia and
New Zealand. Namely, patients
received on average 2 L of IV fluid in
the first 6 h after enrolment, and 4.5 L
in the first 24 h in hospital (including
pre-enrolment). Approximately 30%
required vasopressor support within the
first 24 h, after a median of 2 L of IV
fluid, and 4.7 h from ED triage. A SBP
<90 mmHg and/or lactate ≥2 mmoL/L
was associated with greater fluid admin-
istration, more frequent use of vasopres-
sors, and higher rates of admission to
ICU. Patients receiving larger volume
fluid resuscitation more commonly
needed vasopressors and mechanical
ventilation, and had a longer hospital
stay. Overall, in-hospital mortality
was low (6.2%).
Comparison with other studies
The routine care arms in the ARISE
Early Goal Directed Therapy19 and
Restricted Fluid Resuscitation in Sepsis
associated Hypotension (REFRESH)20
randomised controlled trials delivered
different fluid volumes from pre-
enrolment to 6 h post (4.2 vs 3 L). This
may reflect differences in severity of
disease or inclusion criteria, but could
also suggest adoption of a more fluid
restrictive approach over time. The
routine care group in REFRESH
received a median of 1715 mL
between 0 and 6 h and 4250 mL from
pre-enrolment to 24 h, which is similar
to the overall findings in the current
study.
TABLE 4. Continued
Overall
(n = 584)
0–1000 mL
(n = 188)†
1001–1800 mL
(n = 104)
1801–2501 mL
(n = 147)
>2501 mL
(n = 145)
Duration of ventilation,
days, median (IQR)
5.6 (2.0–7.1) 4.4 (1.4–6.2) 7.8 (0.6–8.4) 6.0 (5.7–7.5) 4.1 (2.0–6.9)
Patients receiving RRT, n (%) 13 (6.1) 2 (4.7) 1 (3.1) 3 (5.7) 7 (8.2)
Duration of RRT,
days, median (IQR)
2.2 (0.6–6.8) 0.9 (0.5–1.3) 4.1 (4.1–4.1) 0.6 (0.2–11) 4.0 (0.9–20)
ICU mortality, n (%) 18 (8.6) 6 (14.3) 4 (12.5) 5 (9.6) 3 (3.6)
Hospital mortality, n (%) 36 (6.3) 12 (6.5) 7 (6.7) 8 (5.5) 9 (6.4)
Hospital length of stay,
days, median (IQR)
5.1 (2.8–10) 4.5 (2.5–8.2) 4.3 (2.8–8.3) 5.8 (6.1–15) 7.0 (3.7–14)
†As 88 patients had exactly 1000 mL administered in the first 6 h, the first and second fluid quartile do not have the same
number of patients. APACHE II: Acute Physiology and Chronic Health Evaluation; RRT, renal replacement therapy; SBP,
systolic blood pressure; T0, time when all three inclusion criteria were met.
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TABLE 5. Baseline characteristics, fluid volume, need for organ support and mortality; overall group and by quartiles of
time to start of vasopressor infusion
Overall
(n = 177)
0–2.7 h
(n = 45)
2.71–4.7 h
(n = 44)
4.71–7.7 h
(n = 44)
>7.71 h
(n = 44)
Female, n (%) 78 (44.1) 20 (44.4) 19 (43.2) 21 (47.7) 18 (40.9)
Age, years, mean (SD) 65.2 (16.3) 68.6 (12.8) 65.5 (18.4) 68.9 (15.3) 58.3 (16.4)
Lactate, mmol/L, median
(IQR)
3.0 (2.0–4.9) 3.7 (2.4–6.3) 2.7 (2.1–4.5) 3.3 (1.7–4.7) 2.8 (1.6–4)
APACHE II score, mean
(SD)
17.8 (6.3) 20.5 (6.2) 18 (6.1) 18.6 (5.7) 14.1 (5.0)
SBP, mmHg, mean (SD) 89 (13.7) 84.3 (12.3) 91.3 (17.6) 88.2 (8.7) 92.5 (12.1)
Time from triage to
antibiotics, mins,
median (IQR)
59 (33–118) 43 (20–71) 53 (27–100) 67 (42–130) 88 (46–196)
Fluid volume administered, mL
Pre-T0 h
Median (IQR) 1250 (1000–2000) 1000 (1000–1650) 1283 (1000–2000) 1475 (1000–2000) 1383 (1000–2000)
Mean (SD) 1533 (6980) 1488 (748) 1533 (678) 1552 (625) 1561 (755)
Between T0 and T6 h
Median (IQR) 2188 (1250–3250) 2260 (1320–3750) 2088 (1188–3475) 2263 (1250–3000) 2102 (1295–3100)
Mean (SD) 2420 (1465) 2582 (1560) 2324 (1431) 2300 (1315) 2466 (1567)
Between T6 and T24 h
Median (IQR) 1710 (950–2500) 1592 (600–2677) 1200 (650–2200) 1120 (943–2000) 2000 (1780–2553)
Mean (SD) 1666 (1145) 1710 (1348) 1435 (1037) 1373 (999) 2134 (1038)
Total: pre-T0–T24 h
Median (IQR) 5300 (4000–7000) 5565 (3600–7350) 5000 (4030–6650) 5156 (3850–6208) 4653 (2750–6003)
Mean (SD) 5567 (2130) 5704 (2425) 5260 (1878) 5141 (2017) 6160 (2072)
Total fluid volume
administered prior to
starting vasopressors,
mL, n
134 44 31 31 21
Median (IQR) 2000 (1500–3000) 2000 (1000–2625) 2000 (2000–3100) 2184 (1750–2854) 3500 (3000–4100)
Mean (SD) 2465 (1280) 2015 (1169) 2565 (1036) 2400 (1074) 3652 (1448)
Vasopressor infusion
started in ED, n (%)
126 (71.2) 43 (95.6) 31 (70.5) 31 (70.5) 21 (47.7)
Vasopressor infusion
started before T24,
n (%)
177 (100) 45 (100) 44 (100) 44 (100) 44 (100)
Duration of vasopressor
infusion, h, median
(IQR)
26.6 (12–48) 32 (11–88) 26 (12–44) 22 (17–38) 31 (8.1–51)
Time to start vasopressor
infusion from T0, h,
median (IQR)
2.5 (0.8–5.0) 0.5 (0–1.25) 2.0 (1.1–2.7) 3.8 (2.2–5.0) 7.1 (4.9–9.5)
Admitted to ICU within
24 h, n (%)
155 (88.1) 42 (93.3) 37 (84.1) 38 (88.4) 38 (86.4)
(Continues)
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The quartile of patients receiving
the lowest fluid volume (median
900 mL administered in the first 6 h
after enrolment and 3 L in the first
24 h), had somewhat less fluid
administered than the restricted vol-
ume arm of REFRESH.20 In contrast,
the quartile of patients in our study
receiving the most fluid were admin-
istered 3.2 L in the first 6 h after
enrolment and 5.4 L from pre-
enrolment to 24 h, with the overall
range of fluid given in the first 24 h
varied between 1 and 12.2 L. These
findings are consistent with sepsis
being a highly variable clinical syn-
drome, where an individualised
approach to fluid resuscitation is
often employed.
Of note was the low in-hospital
mortality observed in the present
study (6.2%, 95% confidence interval
4.5–8.5%), whereas other Austral-
asian studies of patients with sepsis
and hypotension have reported in-
hospital mortality rates between
18 and 25%.21,22 In contrast, and
consistent with our study, when
assessing patients without limitations
of care, the 30-day mortality was
6.2% in a cohort of 399 ED patients
with septic shock in a tertiary hospital
in Australia.21 Temporal improve-
ments of sepsis care and an associated
decrease in mortality in Australia and
New Zealand may also partially
explain our findings.22
Our study used a similar method-
ology to that undertaken in 32 Aus-
tralian and New Zealand hospitals
conducted in 2009.23 However, the
inclusion criteria for that study were
a SBP <90 mmHg despite a 500 mL
bolus or a lactate greater than
4 mmol/L. Notably, all patients with
sepsis were included in the 2009
study, whereas in our study patients
with limitations of care were
excluded. These differences in eligi-
bility may explain the higher
APACHE II score in the 2009 study
compared to ARISE FLUIDS
(19  8.2 vs 15.2  6.7) as well as
the higher mortality (23.1%). In
ARISE 2009, approximately 2 L was
administered between 0 and 6 h,
which was similar to ARISE
FLUIDS. Almost one-third (32%) of
patients received vasopressors in the
first 6 h after enrolment in ARISE
2009, whereas in ARISE FLUIDS a
similar proportion had vasopressors
started before 24 h (30.2%). The
median time to vasopressor com-
mencement was 4.6 h (2.7–7.8)
which was shorter than median time
to central line access of 6.5 h
(3.5–10.1), indicating vasopressor
delivery through a peripheral line
occurred. This practice is supported
by an analysis of patients who
received peripheral vasopressors in the
ARISE Early Goal Directed Therapy
trial19 which showed that this was
associated with some improvements in
processes of care, and not associated
with differential mortality.24 A recent
systematic review concluded when
given for a limited duration and under
close observation, adverse events of
peripheral vasopressors are rare.25
Study implications
Our study found significant hetero-
geneity in fluid volume resuscitation
in hypotensive patients with sepsis,
implying that the clinical environ-
ment might potentially support a
controlled trial in this area.26 With
falling mortality among patients with
sepsis who are eligible for ICU care,
there is a growing recognition that
long-term quality of life among sur-
vivors relates to organ failure.27,28 In
this respect, our data suggest a
potential relationship between
greater fluid volume resuscitation in
the first 6 and 24 h and organ dys-
function, implying that the need for
invasive organ support represents a
logical endpoint for future work.
TABLE 5. Continued
Overall
(n = 177)
0–2.7 h
(n = 45)
2.71–4.7 h
(n = 44)
4.71–7.7 h
(n = 44)
>7.71 h
(n = 44)
Patients receiving invasive
ventilation, n (%)
31 (20.3) 12 (28.6) 8 (22.2) 2 (5.3) 9 (24.3)
Duration of ventilation,
days, median (IQR)
5.6 (5.7–6.5) 2.7 (1.8–7.1) 5.7 (1.8–7.5) 9.5 (5.7–13) 5.2 (2.9–32)
Patients receiving acute
RRT, n (%)
13 (8.6) 3 (7.3) 5 (3.9) 2 (5.4) 3 (8.1)
Duration of RRT, days,
median (IQR)
2.2 (0.6–6.8) 2.2 (0.2–4.0) 4.1 (0.9–6.8) 0.3 (0.2–0.5) 20 (1.3–23)
ICU mortality, n (%) 16 (10.7) 6 (14.6) 2 (5.7) 3 (8.1) 5 (13.9)
Hospital mortality, n (%) 22 (13.1) 6 (14) 4 (9.8) 7 (17.1) 5 (11.6)
Hospital length of stay,
days, median (IQR)
8.6 (4.4–18) 9.3 (4.2–18) 7.8 (4.1–15) 7.1 (4.9–13) 9.8 (4.4–19)
ICU outcomes uses number of patients admitted to ICU as denominator. APACHE II, Acute Physiology and Chronic
Health Evaluation; RRT, renal replacement therapy; SBP, systolic blood pressure; T0, time when all three inclusion criteria
were met.
© 2020 The Authors. Emergency Medicine Australasia published by John Wiley & Sons Australia, Ltd on behalf of Australasian College
for Emergency Medicine
10 G KEIJZERS ET AL.
Finally, our study provided impor-
tant insights into the yield of our
screening procedures. One in every
66 adult ED presentations (1.51%)
were screened with an enrolment
rate of 13.2%, or a ‘number needed
to screen’ of 7.6. This corresponded
with 2 in every 1000 adult atten-
dances in the present study being eli-
gible, which is consistent with prior
research.29
Limitations
The participating sites were self-
selected based on an expression of
interest via the Australasian College for
Emergency Medicine, with data collec-
tion occurring only in spring and sum-
mer. However, the 70 hospitals
represented a wide geographical spread
ranging from tertiary to rural and
remote facilities with varying levels of
onsite ICU facilities. As such we believe
our findings have robust external valid-
ity. Although in-hospital mortality is
lower in this study than most others
performed in similar settings, compari-
sons are difficult to make, as compared
to other studies we did not report
90-day mortality. This was because we
utilised an endpoint more proximal to
the exposure of interest (e.g. fluid
administration in ED), as 90-day mor-
tality is likely to be confounded by
other factors. We excluded 26 patients
where death was imminent and 33with
a life-expectancy <90 days.
It is possible that not all patients
were screened or enrolled. In partic-
ular, the low mortality rate raises
the question as to whether sicker
patients were missed. A more likely
explanation is that patients who
were not eligible for ICU admission
were excluded from our study, par-
ticularly since we had dedicated site
clinician–investigators actively
screening for suitable patients. In
the Australasian ED setting these
patients not eligible for ICU admis-
sion represent a substantial propor-
tion of patients who die as a result
of their sepsis, with mortality rates
varying between 47 and 66%.22,23
Further, missing data were inevita-
ble as patients received routine care
which may not include all relevant
variables. Any ‘missingness’ is
therefore likely to be random.
The observation that an increasing
volume of fluid was associated with a
greater proportion requiring vasopres-
sors and/or mechanical ventilation
should be viewed cautiously.
Although greater fluid administration
has been associated with harm, this is
clearly confounded by illness severity.
In this respect, these data should be
considered hypothesis-generating at
best, and reinforces the need for
future systematic research in this area.
Conclusion
The ARISE FLUIDS observational
study is the largest Australasian
observational study providing a
30-day snapshot of contemporary
ED practice across a wide range of
settings, from rural/regional to met-
ropolitan teaching hospitals. Current
resuscitation practices in patients
with sepsis and hypotension in
Australia and New Zealand vary
widely, occupying the spectrum
between a restricted volume/earlier
vasopressor and liberal fluid/later
vasopressor strategy.
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Supporting information
Additional supporting information
may be found in the online version of
this article at the publisher’s web site:
Table S1. Vital signs and laboratory
results at eligibility (T0) and
6 and 24 h.
Table S2. Main fluid types
administered.
Table S3. Systolic blood pressure at
T0; ≥90 versus <90 mmHg.
Table S4. Lactate at T0. <2 versus
≥2 mmol/L.
Table S5. Systolic blood pressure
<90 and lactate ≥2 mmol/L at T0
versus patients not meeting these
criteria.
Table S6. Abdominal source of sep-
sis versus other source.
Table S7. Respiratory source of sep-
sis versus other source.
Table S8. Age <65 versus ≥65 years.
Table S9. Cardiovascular com-
orbidities absent or present.
Table S10. Severity of illness – by
APACHE II quartiles at T0.
Table S11. Hospital type.
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